Preliminary Updated Results Of A Phase I/Ii Trial Using Trimodality Therapy In Patients With Post-Prostatectomy High Risk Pathologic (P) T2-3n0m0 Prostate Cancer

e16084 Background: We present the updated preliminary results of an on-going phase I / II trial with the purpose of determining the safety, feasibility and efficacy of post-prostatectomy 3-D conformal RT (CRT), hormonal therapy and concurrent docetaxel in patients with high risk pathologic (p) T2-3N0M0 prostate cancer. Methods: Post-prostatectomy high risk prostate cancer was defined as clinically non-metastatic disease with either an undetectable, persistent or rising PSA with 1 or more of the following clinical-pathologic features: (1) pT2-T3aN0 disease, positive or negative margins, with either (a) a gleason score (GS) of ≥8, and/or (b) a PSA doubling time of ≤10 months, and/or (c) with a pre-RT PSA of ≥1.0 ng/ml; and/or (2) pT3bN0 disease. The tri-modality treatment consisted of 6 months of hormonal therapy [Casodex (50 mg po daily), and Zoladex (10.8 mg sc q 3 mos x 2) or Lupron (22.5 mg im q 3 mos x 2)], 3-D CRT to 66.0 Gy at 2.0 Gy/fraction (fx) once daily (50 Gy to the surgical bed followed by a 1...